The global market for Peptide Drug CDMO was valued at US$ 2571 million in the year 2023 and is projected to reach a revised size of US$ 4911 million by 2030, growing at a CAGR of 10.1% during the forecast period.

Peptide Drug CDMO Market

Peptide CDMO refers to an organization that accepts commissions from pharmaceutical companies and engages in the development and production of peptide drugs. These organizations usually have advanced peptide synthesis, purification, analysis and other technologies, and can provide customers with one-stop services from peptide API synthesis, purification, structural identification to formulation development, clinical trials, etc.

As a unique drug compound, peptides are between small molecules and proteins, and are different in biochemistry and treatment. Peptides provide opportunities for therapeutic interventions that closely mimic natural pathways and play a major role in various physiological processes in the human body (including hormones, neurotransmitters) or in inflammatory responses. Peptide drugs have the characteristics of strong selectivity and rapid onset, and can be extracted naturally or synthesized artificially. With multiple advantages such as high purity and controllable quality, they have become popular drugs at present. The medical field is an important application market for peptide substances, and the market demand for peptide drugs is increasing. Based on the complexity and high-tech characteristics of peptide drug development, peptide development and production outsourcing services came into being, that is, peptide CDMO began to appear.

North American market for Peptide Drug CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Peptide Drug CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Peptide Drug CDMO in Antineoplastic Drugs is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Peptide Drug CDMO include Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Peptide Drug CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Drug CDMO.

The Peptide Drug CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Peptide Drug CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Peptide Drug CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Peptide Drug CDMO Market Report

Report Metric	Details
Report Name	Peptide Drug CDMO Market
Accounted market size in year	US$ 2571 million
Forecasted market size in 2030	US$ 4911 million
CAGR	10.1%
Base Year	year
Forecasted years	2024 - 2030
Segment by Type	APIs and Intermediates FDF
Segment by Application	Antineoplastic Drugs Geno-Urinary System and Sex Hormones Cardiovascular System Drugs Anti-Infective Drugs
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, ScinoPharm, SN Biopharm, CBL, Piramal Pharma, CPC Scientific
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Peptide Drug CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Peptide Drug CDMO Market growing?

Ans: The Peptide Drug CDMO Market witnessing a CAGR of 10.1% during the forecast period 2024-2030.

What is the Peptide Drug CDMO Market size in 2030?

Ans: The Peptide Drug CDMO Market size in 2030 will be US$ 4911 million.

Who are the main players in the Peptide Drug CDMO Market report?

Ans: The main players in the Peptide Drug CDMO Market are Bachem, PolyPeptide, CordenPharma, AmbioPharm, USV Peptides, Thermofischer, Bio Basic, JPT, Genscript, Xinbang Pharma, ScinoPharm, SN Biopharm, CBL, Piramal Pharma, CPC Scientific

What are the Application segmentation covered in the Peptide Drug CDMO Market report?

Ans: The Applications covered in the Peptide Drug CDMO Market report are Antineoplastic Drugs, Geno-Urinary System and Sex Hormones, Cardiovascular System Drugs, Anti-Infective Drugs

What are the Type segmentation covered in the Peptide Drug CDMO Market report?

Ans: The Types covered in the Peptide Drug CDMO Market report are APIs and Intermediates, FDF

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Peptide Drug CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030

1.2.2 APIs and Intermediates

1.2.3 FDF

1.3 Market by Application

1.3.1 Global Peptide Drug CDMO Market Growth by Application: 2019 VS 2023 VS 2030

1.3.2 Antineoplastic Drugs

1.3.3 Geno-Urinary System and Sex Hormones

1.3.4 Cardiovascular System Drugs

1.3.5 Anti-Infective Drugs

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Global Growth Trends

2.1 Global Peptide Drug CDMO Market Perspective (2019-2030)

2.2 Global Peptide Drug CDMO Growth Trends by Region

2.2.1 Global Peptide Drug CDMO Market Size by Region: 2019 VS 2023 VS 2030

2.2.2 Peptide Drug CDMO Historic Market Size by Region (2019-2024)

2.2.3 Peptide Drug CDMO Forecasted Market Size by Region (2025-2030)

2.3 Peptide Drug CDMO Market Dynamics

2.3.1 Peptide Drug CDMO Industry Trends

2.3.2 Peptide Drug CDMO Market Drivers

2.3.3 Peptide Drug CDMO Market Challenges

2.3.4 Peptide Drug CDMO Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Peptide Drug CDMO Players by Revenue

3.1.1 Global Top Peptide Drug CDMO Players by Revenue (2019-2024)

3.1.2 Global Peptide Drug CDMO Revenue Market Share by Players (2019-2024)

3.2 Global Peptide Drug CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Global Key Players Ranking by Peptide Drug CDMO Revenue

3.4 Global Peptide Drug CDMO Market Concentration Ratio

3.4.1 Global Peptide Drug CDMO Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Peptide Drug CDMO Revenue in 2023

3.5 Global Key Players of Peptide Drug CDMO Head office and Area Served

3.6 Global Key Players of Peptide Drug CDMO, Product and Application

3.7 Global Key Players of Peptide Drug CDMO, Date of Enter into This Industry

3.8 Mergers & Acquisitions, Expansion Plans

4 Peptide Drug CDMO Breakdown Data by Type

4.1 Global Peptide Drug CDMO Historic Market Size by Type (2019-2024)

4.2 Global Peptide Drug CDMO Forecasted Market Size by Type (2025-2030)

5 Peptide Drug CDMO Breakdown Data by Application

5.1 Global Peptide Drug CDMO Historic Market Size by Application (2019-2024)

5.2 Global Peptide Drug CDMO Forecasted Market Size by Application (2025-2030)

6 North America

6.1 North America Peptide Drug CDMO Market Size (2019-2030)

6.2 North America Peptide Drug CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030

6.3 North America Peptide Drug CDMO Market Size by Country (2019-2024)

6.4 North America Peptide Drug CDMO Market Size by Country (2025-2030)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Peptide Drug CDMO Market Size (2019-2030)

7.2 Europe Peptide Drug CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030

7.3 Europe Peptide Drug CDMO Market Size by Country (2019-2024)

7.4 Europe Peptide Drug CDMO Market Size by Country (2025-2030)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Nordic Countries

8 Asia-Pacific

8.1 Asia-Pacific Peptide Drug CDMO Market Size (2019-2030)

8.2 Asia-Pacific Peptide Drug CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030

8.3 Asia-Pacific Peptide Drug CDMO Market Size by Region (2019-2024)

8.4 Asia-Pacific Peptide Drug CDMO Market Size by Region (2025-2030)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia

9 Latin America

9.1 Latin America Peptide Drug CDMO Market Size (2019-2030)

9.2 Latin America Peptide Drug CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030

9.3 Latin America Peptide Drug CDMO Market Size by Country (2019-2024)

9.4 Latin America Peptide Drug CDMO Market Size by Country (2025-2030)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Peptide Drug CDMO Market Size (2019-2030)

10.2 Middle East & Africa Peptide Drug CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030

10.3 Middle East & Africa Peptide Drug CDMO Market Size by Country (2019-2024)

10.4 Middle East & Africa Peptide Drug CDMO Market Size by Country (2025-2030)

10.5 Turkey

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 Bachem

11.1.1 Bachem Company Details

11.1.2 Bachem Business Overview

11.1.3 Bachem Peptide Drug CDMO Introduction

11.1.4 Bachem Revenue in Peptide Drug CDMO Business (2019-2024)

11.1.5 Bachem Recent Development

11.2 PolyPeptide

11.2.1 PolyPeptide Company Details

11.2.2 PolyPeptide Business Overview

11.2.3 PolyPeptide Peptide Drug CDMO Introduction

11.2.4 PolyPeptide Revenue in Peptide Drug CDMO Business (2019-2024)

11.2.5 PolyPeptide Recent Development

11.3 CordenPharma

11.3.1 CordenPharma Company Details

11.3.2 CordenPharma Business Overview

11.3.3 CordenPharma Peptide Drug CDMO Introduction

11.3.4 CordenPharma Revenue in Peptide Drug CDMO Business (2019-2024)

11.3.5 CordenPharma Recent Development

11.4 AmbioPharm

11.4.1 AmbioPharm Company Details

11.4.2 AmbioPharm Business Overview

11.4.3 AmbioPharm Peptide Drug CDMO Introduction

11.4.4 AmbioPharm Revenue in Peptide Drug CDMO Business (2019-2024)

11.4.5 AmbioPharm Recent Development

11.5 USV Peptides

11.5.1 USV Peptides Company Details

11.5.2 USV Peptides Business Overview

11.5.3 USV Peptides Peptide Drug CDMO Introduction

11.5.4 USV Peptides Revenue in Peptide Drug CDMO Business (2019-2024)

11.5.5 USV Peptides Recent Development

11.6 Thermofischer

11.6.1 Thermofischer Company Details

11.6.2 Thermofischer Business Overview

11.6.3 Thermofischer Peptide Drug CDMO Introduction

11.6.4 Thermofischer Revenue in Peptide Drug CDMO Business (2019-2024)

11.6.5 Thermofischer Recent Development

11.7 Bio Basic

11.7.1 Bio Basic Company Details

11.7.2 Bio Basic Business Overview

11.7.3 Bio Basic Peptide Drug CDMO Introduction

11.7.4 Bio Basic Revenue in Peptide Drug CDMO Business (2019-2024)

11.7.5 Bio Basic Recent Development

11.8 JPT

11.8.1 JPT Company Details

11.8.2 JPT Business Overview

11.8.3 JPT Peptide Drug CDMO Introduction

11.8.4 JPT Revenue in Peptide Drug CDMO Business (2019-2024)

11.8.5 JPT Recent Development

11.9 Genscript

11.9.1 Genscript Company Details

11.9.2 Genscript Business Overview

11.9.3 Genscript Peptide Drug CDMO Introduction

11.9.4 Genscript Revenue in Peptide Drug CDMO Business (2019-2024)

11.9.5 Genscript Recent Development

11.10 Xinbang Pharma

11.10.1 Xinbang Pharma Company Details

11.10.2 Xinbang Pharma Business Overview

11.10.3 Xinbang Pharma Peptide Drug CDMO Introduction

11.10.4 Xinbang Pharma Revenue in Peptide Drug CDMO Business (2019-2024)

11.10.5 Xinbang Pharma Recent Development

11.11 ScinoPharm

11.11.1 ScinoPharm Company Details

11.11.2 ScinoPharm Business Overview

11.11.3 ScinoPharm Peptide Drug CDMO Introduction

11.11.4 ScinoPharm Revenue in Peptide Drug CDMO Business (2019-2024)

11.11.5 ScinoPharm Recent Development

11.12 SN Biopharm

11.12.1 SN Biopharm Company Details

11.12.2 SN Biopharm Business Overview

11.12.3 SN Biopharm Peptide Drug CDMO Introduction

11.12.4 SN Biopharm Revenue in Peptide Drug CDMO Business (2019-2024)

11.12.5 SN Biopharm Recent Development

11.13 CBL

11.13.1 CBL Company Details

11.13.2 CBL Business Overview

11.13.3 CBL Peptide Drug CDMO Introduction

11.13.4 CBL Revenue in Peptide Drug CDMO Business (2019-2024)

11.13.5 CBL Recent Development

11.14 Piramal Pharma

11.14.1 Piramal Pharma Company Details

11.14.2 Piramal Pharma Business Overview

11.14.3 Piramal Pharma Peptide Drug CDMO Introduction

11.14.4 Piramal Pharma Revenue in Peptide Drug CDMO Business (2019-2024)

11.14.5 Piramal Pharma Recent Development

11.15 CPC Scientific

11.15.1 CPC Scientific Company Details

11.15.2 CPC Scientific Business Overview

11.15.3 CPC Scientific Peptide Drug CDMO Introduction

11.15.4 CPC Scientific Revenue in Peptide Drug CDMO Business (2019-2024)

11.15.5 CPC Scientific Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Peptide Drug CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030

Table 2. Key Players of APIs and Intermediates

Table 3. Key Players of FDF

Table 4. Global Peptide Drug CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030

Table 5. Global Peptide Drug CDMO Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 6. Global Peptide Drug CDMO Market Size by Region (2019-2024) & (US$ Million)

Table 7. Global Peptide Drug CDMO Market Share by Region (2019-2024)

Table 8. Global Peptide Drug CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)

Table 9. Global Peptide Drug CDMO Market Share by Region (2025-2030)

Table 10. Peptide Drug CDMO Market Trends

Table 11. Peptide Drug CDMO Market Drivers

Table 12. Peptide Drug CDMO Market Challenges

Table 13. Peptide Drug CDMO Market Restraints

Table 14. Global Peptide Drug CDMO Revenue by Players (2019-2024) & (US$ Million)

Table 15. Global Peptide Drug CDMO Market Share by Players (2019-2024)

Table 16. Global Top Peptide Drug CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Drug CDMO as of 2023)

Table 17. Ranking of Global Top Peptide Drug CDMO Companies by Revenue (US$ Million) in 2023

Table 18. Global 5 Largest Players Market Share by Peptide Drug CDMO Revenue (CR5 and HHI) & (2019-2024)

Table 19. Global Key Players of Peptide Drug CDMO, Headquarters and Area Served

Table 20. Global Key Players of Peptide Drug CDMO, Product and Application

Table 21. Global Key Players of Peptide Drug CDMO, Date of Enter into This Industry

Table 22. Mergers & Acquisitions, Expansion Plans

Table 23. Global Peptide Drug CDMO Market Size by Type (2019-2024) & (US$ Million)

Table 24. Global Peptide Drug CDMO Revenue Market Share by Type (2019-2024)

Table 25. Global Peptide Drug CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)

Table 26. Global Peptide Drug CDMO Revenue Market Share by Type (2025-2030)

Table 27. Global Peptide Drug CDMO Market Size by Application (2019-2024) & (US$ Million)

Table 28. Global Peptide Drug CDMO Revenue Market Share by Application (2019-2024)

Table 29. Global Peptide Drug CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)

Table 30. Global Peptide Drug CDMO Revenue Market Share by Application (2025-2030)

Table 31. North America Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 32. North America Peptide Drug CDMO Market Size by Country (2019-2024) & (US$ Million)

Table 33. North America Peptide Drug CDMO Market Size by Country (2025-2030) & (US$ Million)

Table 34. Europe Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 35. Europe Peptide Drug CDMO Market Size by Country (2019-2024) & (US$ Million)

Table 36. Europe Peptide Drug CDMO Market Size by Country (2025-2030) & (US$ Million)

Table 37. Asia-Pacific Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 38. Asia-Pacific Peptide Drug CDMO Market Size by Region (2019-2024) & (US$ Million)

Table 39. Asia-Pacific Peptide Drug CDMO Market Size by Region (2025-2030) & (US$ Million)

Table 40. Latin America Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 41. Latin America Peptide Drug CDMO Market Size by Country (2019-2024) & (US$ Million)

Table 42. Latin America Peptide Drug CDMO Market Size by Country (2025-2030) & (US$ Million)

Table 43. Middle East & Africa Peptide Drug CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030

Table 44. Middle East & Africa Peptide Drug CDMO Market Size by Country (2019-2024) & (US$ Million)

Table 45. Middle East & Africa Peptide Drug CDMO Market Size by Country (2025-2030) & (US$ Million)

Table 46. Bachem Company Details

Table 47. Bachem Business Overview

Table 48. Bachem Peptide Drug CDMO Product

Table 49. Bachem Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 50. Bachem Recent Development

Table 51. PolyPeptide Company Details

Table 52. PolyPeptide Business Overview

Table 53. PolyPeptide Peptide Drug CDMO Product

Table 54. PolyPeptide Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 55. PolyPeptide Recent Development

Table 56. CordenPharma Company Details

Table 57. CordenPharma Business Overview

Table 58. CordenPharma Peptide Drug CDMO Product

Table 59. CordenPharma Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 60. CordenPharma Recent Development

Table 61. AmbioPharm Company Details

Table 62. AmbioPharm Business Overview

Table 63. AmbioPharm Peptide Drug CDMO Product

Table 64. AmbioPharm Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 65. AmbioPharm Recent Development

Table 66. USV Peptides Company Details

Table 67. USV Peptides Business Overview

Table 68. USV Peptides Peptide Drug CDMO Product

Table 69. USV Peptides Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 70. USV Peptides Recent Development

Table 71. Thermofischer Company Details

Table 72. Thermofischer Business Overview

Table 73. Thermofischer Peptide Drug CDMO Product

Table 74. Thermofischer Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 75. Thermofischer Recent Development

Table 76. Bio Basic Company Details

Table 77. Bio Basic Business Overview

Table 78. Bio Basic Peptide Drug CDMO Product

Table 79. Bio Basic Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 80. Bio Basic Recent Development

Table 81. JPT Company Details

Table 82. JPT Business Overview

Table 83. JPT Peptide Drug CDMO Product

Table 84. JPT Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 85. JPT Recent Development

Table 86. Genscript Company Details

Table 87. Genscript Business Overview

Table 88. Genscript Peptide Drug CDMO Product

Table 89. Genscript Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 90. Genscript Recent Development

Table 91. Xinbang Pharma Company Details

Table 92. Xinbang Pharma Business Overview

Table 93. Xinbang Pharma Peptide Drug CDMO Product

Table 94. Xinbang Pharma Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 95. Xinbang Pharma Recent Development

Table 96. ScinoPharm Company Details

Table 97. ScinoPharm Business Overview

Table 98. ScinoPharm Peptide Drug CDMO Product

Table 99. ScinoPharm Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 100. ScinoPharm Recent Development

Table 101. SN Biopharm Company Details

Table 102. SN Biopharm Business Overview

Table 103. SN Biopharm Peptide Drug CDMO Product

Table 104. SN Biopharm Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 105. SN Biopharm Recent Development

Table 106. CBL Company Details

Table 107. CBL Business Overview

Table 108. CBL Peptide Drug CDMO Product

Table 109. CBL Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 110. CBL Recent Development

Table 111. Piramal Pharma Company Details

Table 112. Piramal Pharma Business Overview

Table 113. Piramal Pharma Peptide Drug CDMO Product

Table 114. Piramal Pharma Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 115. Piramal Pharma Recent Development

Table 116. CPC Scientific Company Details

Table 117. CPC Scientific Business Overview

Table 118. CPC Scientific Peptide Drug CDMO Product

Table 119. CPC Scientific Revenue in Peptide Drug CDMO Business (2019-2024) & (US$ Million)

Table 120. CPC Scientific Recent Development

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

Table 124. Authors List of This Report

List of Figures

Figure 1. Peptide Drug CDMO Picture

Figure 2. Global Peptide Drug CDMO Market Size Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Peptide Drug CDMO Market Share by Type: 2023 VS 2030

Figure 4. APIs and Intermediates Features

Figure 5. FDF Features

Figure 6. Global Peptide Drug CDMO Market Size by Application (2024-2030) & (US$ Million)

Figure 7. Global Peptide Drug CDMO Market Share by Application: 2023 VS 2030

Figure 8. Antineoplastic Drugs Case Studies

Figure 9. Geno-Urinary System and Sex Hormones Case Studies

Figure 10. Cardiovascular System Drugs Case Studies

Figure 11. Anti-Infective Drugs Case Studies

Figure 12. Peptide Drug CDMO Report Years Considered

Figure 13. Global Peptide Drug CDMO Market Size (US$ Million), Year-over-Year: 2019-2030

Figure 14. Global Peptide Drug CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030

Figure 15. Global Peptide Drug CDMO Market Share by Region: 2023 VS 2030

Figure 16. Global Peptide Drug CDMO Market Share by Players in 2023

Figure 17. Global Top Peptide Drug CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Drug CDMO as of 2023)

Figure 18. The Top 10 and 5 Players Market Share by Peptide Drug CDMO Revenue in 2023

Figure 19. North America Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 20. North America Peptide Drug CDMO Market Share by Country (2019-2030)

Figure 21. United States Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 22. Canada Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 23. Europe Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 24. Europe Peptide Drug CDMO Market Share by Country (2019-2030)

Figure 25. Germany Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 26. France Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 27. U.K. Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 28. Italy Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 29. Russia Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 30. Nordic Countries Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 31. Asia-Pacific Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 32. Asia-Pacific Peptide Drug CDMO Market Share by Region (2019-2030)

Figure 33. China Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 34. Japan Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 35. South Korea Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 36. Southeast Asia Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 37. India Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 38. Australia Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 39. Latin America Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 40. Latin America Peptide Drug CDMO Market Share by Country (2019-2030)

Figure 41. Mexico Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 42. Brazil Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 43. Middle East & Africa Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 44. Middle East & Africa Peptide Drug CDMO Market Share by Country (2019-2030)

Figure 45. Turkey Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 46. Saudi Arabia Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 47. UAE Peptide Drug CDMO Market Size YoY Growth (2019-2030) & (US$ Million)

Figure 48. Bachem Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 49. PolyPeptide Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 50. CordenPharma Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 51. AmbioPharm Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 52. USV Peptides Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 53. Thermofischer Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 54. Bio Basic Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 55. JPT Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 56. Genscript Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 57. Xinbang Pharma Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 58. ScinoPharm Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 59. SN Biopharm Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 60. CBL Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 61. Piramal Pharma Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 62. CPC Scientific Revenue Growth Rate in Peptide Drug CDMO Business (2019-2024)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Substrate Cutting Device Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-23Z18292

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Targeted Radionuclide Drug - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-14Z15017

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Global Microfluidic Single-Cell Analysis and Screening System Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-7M18883

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

Medicinal Liquid Filling Equipment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages

Type: Report

Code: QYRE-Auto-37J14968

Thu Dec 12 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions